All In MedTech

Device Trial Radar · NCT04131907

Optilume™ BPH Catheter System in Men With Symptomatic BPH

A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPH

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

162

Actual

Start

Feb 5, 2020

Primary completion

Aug 23, 2022

Study completion May 2027

Sponsor

Lead sponsor
Urotronic Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 18, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • Optilume BPH Catheter SystemDevice

    The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.

  • Optilume Sham DeviceDevice

    21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With >30% Improvement in the International Prostate Symptom Score (IPSS)Time frame: 12 months
  2. Number of Participants With Major Device Related Serious ComplicationsTime frame: 12 months

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Arkansas Urology

    Little Rock, Arkansas

  • Colorado Clinical Research

    Golden, Colorado

  • Advanced Urology Institute

    Daytona Beach, Florida

18 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.